Stephens & Co. analyst Matt Breese downgrades First Commonwealth (NYSE:FCF) from Overweight to Equal-Weight and announces $15.5 price target.
Gilead And Arcus Biosciences Announce Positive Update On Joint TIGIT Program From Interim Analysis of ARC-7 Study In Non-Small Cell Lung Cancer; Shares Spike Higher
– Fourth Interim Analysis Shows Continued Clinically Meaningful Differentiation Across All Efficacy Measures, Including PFS, in Both Domvanalimab-Containing Arms Compared to the Anti-PD-1 Zimberelimab Monotherapy
